Alimera Sciences, Inc. (ALIM)
NASDAQ: ALIM · Real-Time Price · USD
5.59
+0.01 (0.18%)
Aug 23, 2024, 4:00 PM EDT - Market closed
Alimera Sciences Employees
As of December 31, 2023, Alimera Sciences had 159 total employees, including 154 full-time and 5 part-time employees. The number of employees increased by 1 or 0.63% compared to the previous year.
Employees
159
Change (1Y)
1
Growth (1Y)
0.63%
Revenue / Employee
$626,925
Profits / Employee
-$96,057
Market Cap
304.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AngioDynamics | 748 |
Adaptimmune Therapeutics | 449 |
Editas Medicine | 265 |
Vanda Pharmaceuticals | 203 |
Akebia Therapeutics | 167 |
Nautilus Biotechnology | 167 |
AC Immune | 161 |
TScan Therapeutics | 154 |
ALIM News
- 4 days ago - ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM - Business Wire
- 18 days ago - Alimera Sciences Reports Second Quarter 2024 Results - GlobeNewsWire
- 2 months ago - Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher - Benzinga
- 2 months ago - Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal - Invezz
- 2 months ago - Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Alimera Sciences Reports First Quarter 2024 Results - GlobeNewsWire
- 5 months ago - Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network - GlobeNewsWire